Introduction {#sec1}
============

The number of patients undergoing total knee arthroplasty (TKA) has increased substantially in the last two decades, and currently, TKA is one of the most common orthopaedic procedures performed in the United States [@bib1]. For many patients, pain after TKA can be severe and can compromise postoperative management leading to poor outcomes. Using a multimodal pain management protocol has been shown to improve pain scores, increase patient satisfaction, and enhance early recovery [@bib2]. Currently, there are many postoperative pain management protocols used by orthopaedic surgeons. Regional nerve blocks and local infiltrative analgesia are two techniques that have been shown to provide postoperative pain relief, lower narcotic usage, and improve patient satisfaction in the early postoperative period [@bib3]. Liposomal bupivacaine, Exparel (Pacira Pharmaceuticals, Parsippany, NJ), is an extended-release local anesthetic that uses multivesicular liposomes to diffuse bupivacaine over a period of 72 hours after single injection at the operative site [@bib4]. Postoperative pain reduction extended for a period of up to 72 hours would benefit the patient by allowing for a more accelerated rehabilitation protocol, which ultimately will lead to shorter length of hospital stay and improved outcomes. In other surgical procedures, liposomal bupivacaine has been shown to offer multiple clinical advantages over short-acting bupivacaine HCl. After hemorrhoidectomy, it demonstrated a longer duration of action, decreased opioid requirement, and fewer opioid-related adverse effects [@bib5]. Extended-release bupivacaine has also been shown to provide extended pain relief and decreased opioid use after bunionectomy compared to a placebo-controlled group [@bib6].

The purpose of this retrospective study was to understand the contribution to pain control and recovery after primary TKA that liposomal bupivacaine adds in the setting of a comprehensive pain protocol. Narcotic usage, length of hospital stay, and walking distance were the primary outcomes investigated. In addition, we aimed to stratify this patient cohort based on comorbidities and body mass index (BMI) to provide insight into which patient populations will benefit most from periarticular injection (PAI) using liposomal bupivacaine.

Material and methods {#sec2}
====================

Fifty consecutive patients who underwent primary TKA and received an intraoperative PAI using liposomal bupivacaine between April 2013 and August 2013 were retrospectively reviewed. A separate cohort of fifty consecutive patients who underwent primary TKA without PAI between June 2012 and August 2012 were retrospectively included as a control group. All procedures were performed by a single surgeon. This study was approved by our institutional review board and was Health Insurance Portability and Accountability Act compliant.

All patients received a single-shot femoral and sciatic nerve block performed by the anesthesia staff, and all patients received intravenous sedation unless general anesthesia was required for better airway control. A subvastus approach was the primary mode of exposure in both groups unless there was a contraindication. All cases were performed using a Stryker Triathlon TKA implant (Stryker, Mahwah, NJ). In the study group, the intraoperative PAI was performed after all components were implanted; the wound was irrigated with a dilute Betadine (Purdue Products LT, Stanford, CT 06901) irrigation and was then washed with normal saline from a pulse irrigator. The PAI was administered according to the liposomal bupivacaine manufacturer's instructions. The PAI consisted of 20 mL of 1.3% liposomal bupivacaine (1 vial; 266 mg) diluted with 40-mL normal saline to create a total injection volume of 60 mL. The control group did not receive any type of intraoperative PAI.

The postoperative pain control regimen was the same for both groups and included the use of oral acetaminophen, celecoxib, tramadol, patient-controlled analgesia, and oral narcotics. Patient-controlled analgesia was administered using morphine, unless contraindicated, at which point hydromorphone was substituted. All postoperative pain medications administered were tabulated and converted to a total oral morphine equivalent (mg) for use in the comparison of the two groups ([Table 1](#tbl1){ref-type="table"}) [@bib7].

A standardized physical therapy protocol was initiated for each group on postoperative day 1. The physical therapy regimen consisted of 2 hours of continuous passive motion machine twice daily, assisted standing, and assisted walking. All patients were discharged when deemed medically stable, their pain was under control, and the physical therapy goals were met.

Standard statistical Student's *t* tests were used to evaluate the mean outcome of continuous variables between groups, and chi-square tests were used to evaluate categorical variables. Dedicated statistical software (SPSS 22; SPSS Inc., Chicago, IL) was used to perform the data analysis. The two groups were compared on the basis of length of hospital stay; amount of narcotic pain medication used over the first 24, 48, and 72 hours; and the distance walked on postoperative days 1, 2, and 3. Statistically significant difference was considered at P ≤ .05 between groups.

Results {#sec3}
=======

Fifty consecutive patients were identified in the study group, consisting of 34 female and 16 male patients, with an average age of 64 (range: 46-88) years and an average BMI of 35 (range: 21-58). This was compared to the control group of 50 consecutive patients, consisting of 32 female and 18 male patients, with an average age of 64 (range: 38-85) years and an average BMI of 35 (range: 20-63). The average Charlson comorbidity index (CCI) for the study group was 3.34 (range: 2-6), and for the control group, it was 3.58 (range: 0-8). There were no statistically significant differences between the groups with respect to gender, age, BMI, comorbidities, or surgical approach. The cohort characteristics are outlined in [Table 2](#tbl2){ref-type="table"}.

There was a statistically significant reduction in the amount of narcotics used over the 48-72-hour postoperative period in the liposomal bupivacaine group (60.97-mg oral morphine equivalent vs 89.74 mg, *P* = .009). There was no statistical difference between the two groups with respect to length of hospital stay, amount of narcotics used from 0-24 hours and 24-48 hours, or the postoperative walking distance ([Table 3](#tbl3){ref-type="table"}).

When a subset analysis was performed, the patients from the study group with a BMI \<40 and a CCI of 0-3 were found to have a statistically significant difference with respect to length of stay (2.64 vs 3.06 days, *P* = .004), narcotic use over 24-48 hours (110.66 vs 182.47 mg, *P* = .013), and narcotic use over 48-72 hours (49.61 vs 112.65 mg, *P* = .004). There was a trend toward increased walking distance on postoperative day 2 (114.77 vs 84.82 ft, *P* = .193), but this was not statistically significant with the numbers available for study ([Table 4](#tbl4){ref-type="table"}). All other subsets reviewed did not show any statistically significant differences between the two groups with the numbers available for review ([Table 5](#tbl5){ref-type="table"}, [Table 6](#tbl6){ref-type="table"}, [Table 7](#tbl7){ref-type="table"}).

Discussion {#sec4}
==========

Periarticular injections after TKA have been widely used to alleviate postoperative pain to improve patient satisfaction and outcomes [@bib8], [@bib9]. Many groups have used these injections as part of their multimodal pain control management plan after TKA. The use of liposomal bupivacaine as a PAI is a novel technique that can provide long-acting postoperative pain relief [@bib10], [@bib11].

This retrospective study was undertaken to determine whether the addition of a PAI using liposomal bupivacaine compared to no PAI would enhance the postoperative pain relief of patients undergoing TKA. Based on our study, the use of a liposomal bupivacaine PAI led to a decrease in narcotic use in the immediate postoperative period in patients undergoing primary TKA. Patients receiving liposomal bupivacaine were able to be discharged from the hospital sooner and had a trend toward increased walking distance earlier in their postoperative course. The greatest benefit was seen for the healthier (CCI, ≤3) and nonmorbidly obese patients (BMI, \<40). No statistically significant difference in length of stay, narcotic use, or walking distance was noted when comparing morbidly obese (BMI, \>40) patients and those with multiple comorbidities (CCI, \>3). Patients most likely to benefit from the addition of a PAI using liposomal bupivacaine in this study were those with a BMI \<40 and a CCI ≤3.

There are limitations to this study, but despite being a retrospective review, this study was performed at a single institution using consecutive patients, without variation in surgical technique, anesthesia, or the postoperative protocol. The study cohort and control groups both consisted of a consecutive series of patients that underwent primary TKA during a similar time period of the year to best eliminate selection bias. There are several questions that arise from the results of this study, which need further exploration. There is an added cost to each case using liposomal bupivacaine as a PAI. In a study by Bagsby et al [@bib12], they concluded that liposomal bupivacaine PAIs provided inferior pain control compared to the less-expensive traditional PAI using short-acting bupivacaine. However, this was also a retrospective study with two different surgeons, and the authors acknowledge that the results may be technique dependent. It is also important to note that this study compared PAI using liposomal bupivacaine versus short-acting bupivacaine, in comparison to our study, which compared liposomal bupivacaine to no PAI in the control group. A prospective, randomized study by Schroer et al [@bib13] that comparing liposomal bupivacaine to standard bupivacaine did not show any significant benefit between the two periarticular injections in patients undergoing primary TKA. Long-acting pain relief with the use of PAIs appears to be an important part of a multimodal pain regimen that allows for earlier discharge and improved outcomes. There is increasing evidence that short-stay and outpatient TKA is feasible in the near future [@bib14]. Long-acting pain relief through the use of PAI may allow for this to become a possibility. We demonstrated that healthier patients and those with a BMI \<40 had a shorter hospital stay and used fewer narcotics with the use of liposomal bupivacaine. Patients who are morbidly obese and with multiple medical problems may have difficulty in earlier return to function because of their inherent comorbid conditions despite the use of PAIs. In addition, it is not clear whether there are any differences in absorption and release of these PAIs in the morbidly obese patients because of the excess adipose tissue. Additional studies are required to demonstrate the true benefits of liposomal bupivacaine with respect to cost effectiveness compared to a hospital pharmacy--prepared PAI, actual duration of pain relief, and its role in outpatient or short-stay hospitalization after TKA.

Conclusions {#sec5}
===========

Periarticular TKA injection using liposomal bupivacaine in patients with a BMI of less than 40 kg/m2 and a comorbidity index of less than or equal to 3 leads to earlier hospital discharge and decreased narcotic usage.

Appendix. Supplementary data {#appsec1}
============================
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###### 

Equianalgesic conversion.

  Drug            Administration   Dose (mg)   Conversion factor   PO morphine equivalent dose (mg)
  --------------- ---------------- ----------- ------------------- ----------------------------------
  Morphine        PO               10          1                   10
  IV              10               3           30                  
  Hydromorphone   PO               10          4                   40
  IV              10               20          200                 
  Hydrocodone     PO               10          1                   10
  Oxycodone       PO               10          1.5                 15
  Tramadol        PO               10          0.25                2.5

PO, oral; IV, intravenous.

###### 

Cohort characteristics.

  Demographics   Liposomal bupivacaine PAI   No PAI       Chi square   df   *P* value
  -------------- --------------------------- ------------ ------------ ---- -----------
  Male           16                          18           0.18         1    0.67
  Female         34                          32                             
                                                          *P* value         
  Age            64 (46-88)                  64 (38-85)   0.837             
  BMI            35 (21-58)                  35 (20-63)   0.93              
  CCI            3.34 (2-6)                  3.58 (0-8)   0.366             
                                                          Chi square   df   *P* value
  Subvastus      33                          39           1.79         1    0.18
  Parapatellar   17                          11                             

df, degrees of freedom; PAI, periarticular injection.

###### 

Outcomes in all patients.

  Outcome & Narcotic Usage      Liposomal bupivacaine PAI   No PAI   P value
  ----------------------------- --------------------------- -------- -----------
  Length of stay (d)            2.94                        3.26     0.092
  Narcotic use 0-24 h (mg)      119.04                      111.58   0.608
  Narcotic use 24-48 h (mg)     114.74                      132.18   0.217
  Narcotic use 48-72 h (mg)     60.97                       89.74    **0.009**
  Walking distance POD 1 (ft)   61.32                       44.5     0.067
  Walking distance POD 2 (ft)   97.15                       81.42    0.229
  Walking distance POD 3 (ft)   101.93                      123.07   0.246

POD, postoperative day; PAI, periarticular injection.

###### 

Outcomes in patients with BMI \<40, CCI 0-3.

  Outcome & narcotic usage      Liposomal bupivacaine PAI   No PAI   *P* value
  ----------------------------- --------------------------- -------- -----------
  Length of stay (d)            2.64                        3.06     **0.004**
  Narcotic use 0-24 h (mg)      117.61                      145.53   0.298
  Narcotic use 24-48 h (mg)     110.66                      182.47   **0.013**
  Narcotic use 48-72 h (mg)     49.61                       112.65   **0.004**
  Walking distance POD 1 (ft)   73.29                       59.07    0.456
  Walking distance POD 2 (ft)   114.77                      84.82    0.193
  Walking distance POD 3 (ft)   137.27                      119.38   0.545

POD, postoperative day; PAI, periarticular injection; BMI, body mass index; CCI, Charlson comorbidity index.

###### 

Outcomes in patients with BMI \<40, CCI \>3.

  Outcome & narcotic usage      Liposomal bupivacaine PAI   No PAI   *P* value
  ----------------------------- --------------------------- -------- -----------
  Length of stay (d)            3.07                        3.55     0.252
  Narcotic use 0-24 h (mg)      109.8                       87.5     0.283
  Narcotic use 24-48 h (mg)     108.93                      92.23    0.228
  Narcotic use 48-72 h (mg)     75.38                       68.57    0.716
  Walking distance POD 1 (ft)   61.43                       40.95    0.08
  Walking distance POD 2 (ft)   81.64                       78.23    0.828
  Walking distance POD 3 (ft)   82                          122.1    0.176

POD, postoperative day; PAI, periarticular injection; BMI, body mass index; CCI, Charlson comorbidity index.

###### 

Outcomes in patients with BMI \>40, CCI 0-3.

  Outcome & narcotic usage      Liposomal bupivacaine PAI   No PAI   P value
  ----------------------------- --------------------------- -------- ---------
  Length of stay (d)            3                           3        1
  Narcotic use 0-24 h (mg)      156.5                       99.63    0.106
  Narcotic use 24-48 h (mg)     155.39                      126.75   0.38
  Narcotic use 48-72 h (mg)     80                          83.43    0.867
  Walking distance POD 1 (ft)   45.56                       31.43    0.482
  Walking distance POD 2 (ft)   94.38                       109.38   0.738
  Walking distance POD 3 (ft)   96.67                       156.67   0.214

POD, postoperative day; PAI, periarticular injection; BMI, body mass index; CCI, Charlson comorbidity index.

###### 

Outcomes in patients with BMI \>40, CCI \> 3.

  Outcome & narcotic usage      Liposomal bupivacaine PAI   No PAI   *P* value
  ----------------------------- --------------------------- -------- -----------
  Length of stay (d)            4                           3        0.391
  Narcotic use 0-24 h (mg)      77.25                       119.67   0.618
  Narcotic use 24-48 h (mg)     67.5                        154.67   0.254
  Narcotic use 48-72 h (mg)     30                          125      0.237
  Walking distance POD 1 (ft)   24.33                       3        0.472
  Walking distance POD 2 (ft)   47.67                       11       0.28

POD, postoperative day; PAI, periarticular injection; BMI, body mass index; CCI, Charlson comorbidity index.
